A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Cerubidine Side Effects, and Drug Interactions - Daunorubicin
Cerubidine Side Effects, and Drug Interactions - Daunorubicin
SIDE EFFECTS
Dose-limiting toxicity includes myelosuppression and cardiotoxicity (See WARNINGS
section). Other reactions include:
Cutaneous: Reversible alopecia occurs in most patients.
Rash, contact dermatitis and urticaria have occurred rarely.
Gastrointestinal: Acute nausea and vomiting occur but are
usually mild. Antiemetic therapy may be of some help. Mucositis may occur 3
to 7 days after administration. Diarrhea and abdominal pain have occasionally
been reported.
Local: If extravasation occurs during administration, severe
local tissue necrosis, severe cellulitis, thrombophlebitis, or painful induration
can result.
Acute Reactions: Rarely, anaphylactoid reaction, fever,
and chills can occur. Hyperuricemia may occur, especially in patients with leukemia,
and serum uric acid levels should be monitored.
DRUG INTERACTIONS
Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity. Cerubidine
should not be used in patients who have previously received the recommended
maximum cumulative doses of doxorubicin or Cerubidine. Cyclophosphamide used
concurrently with Cerubidine may also result in increased cardiotoxicity.
Dosage reduction of Cerubidine may be required when used concurrently with
other myelosuppressive agents.
Hepatotoxic medications, such as high-dose methotrexate, may impair liver function
and increase the risk of toxicity.
top
